TP53 and neoplasm: We analyzed the expression of immune genes with TP53-MUT and suggested that TP53 mutations regulate the TIME via upregulating expression of HLA and downregulating PGC. Additionally, previous studies have demonstrated that CD8 and CD4 T cell infiltration activation is not only the basis of tumor immunotherapy but also a prognostic indicator of whether the patient is responsive to immunotherapeutic agents [28].